Perspective Therapeutics (NYSE:CATX) Price Target Raised to $16.00 at Royal Bank of Canada

Perspective Therapeutics (NYSE:CATX) had its price target upped by Royal Bank of Canada from $15.00 to $16.00 in a report released on Tuesday morning,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Several other research analysts have also commented on CATX. Scotiabank began coverage on shares of Perspective Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target on the stock. Cantor Fitzgerald raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. Wedbush restated an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a report on Tuesday, May 13th. Lifesci Capital upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Thursday, March 6th. Finally, Truist Financial cut their price objective on Perspective Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $12.63.

Perspective Therapeutics Price Performance

CATX opened at $3.09 on Tuesday. Perspective Therapeutics has a 1 year low of $1.60 and a 1 year high of $16.55. The company’s 50 day simple moving average is $2.27 and its 200 day simple moving average is $2.95.

Insiders Place Their Bets

In other Perspective Therapeutics news, CEO Johan M. Spoor acquired 22,026 shares of the company’s stock in a transaction on Friday, March 28th. The shares were bought at an average cost of $2.24 per share, for a total transaction of $49,338.24. Following the acquisition, the chief executive officer now directly owns 59,383 shares of the company’s stock, valued at $133,017.92. This trade represents a 58.96% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert F. Williamson III bought 22,192 shares of the business’s stock in a transaction on Friday, March 28th. The stock was acquired at an average cost of $2.27 per share, for a total transaction of $50,375.84. Following the completion of the transaction, the director now owns 70,837 shares in the company, valued at $160,799.99. This represents a 45.62% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 115,696 shares of company stock worth $256,344 in the last quarter. 3.72% of the stock is owned by corporate insiders.

Institutional Trading of Perspective Therapeutics

Several institutional investors have recently added to or reduced their stakes in CATX. BNP Paribas Financial Markets increased its position in shares of Perspective Therapeutics by 7.4% in the 4th quarter. BNP Paribas Financial Markets now owns 51,094 shares of the company’s stock worth $163,000 after purchasing an additional 3,529 shares during the last quarter. Rhumbline Advisers grew its stake in Perspective Therapeutics by 4.5% in the fourth quarter. Rhumbline Advisers now owns 94,992 shares of the company’s stock worth $303,000 after purchasing an additional 4,075 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Perspective Therapeutics by 3.4% in the fourth quarter. Bank of New York Mellon Corp now owns 143,469 shares of the company’s stock worth $458,000 after purchasing an additional 4,693 shares in the last quarter. ProShare Advisors LLC increased its holdings in Perspective Therapeutics by 49.1% in the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock valued at $49,000 after buying an additional 5,011 shares during the last quarter. Finally, Nicholson Wealth Management Group LLC raised its stake in Perspective Therapeutics by 0.4% during the fourth quarter. Nicholson Wealth Management Group LLC now owns 1,609,283 shares of the company’s stock valued at $5,134,000 after buying an additional 7,000 shares in the last quarter. 54.66% of the stock is owned by institutional investors and hedge funds.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.